LT - PHARMACEUTICAL COMBINATIONS COMPRISING (A) THE CYCLIN DEPENDENT KINASE 4/6 (CDK4/6) INHIBITOR LEE011 (=RIBOCICLIB), AND (B) THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR ERLOTINIB, FOR THE TREATMENT OR PREVENTION OF CANCER
EN - PHARMACEUTICAL COMBINATIONS COMPRISING (A) THE CYCLIN DEPENDENT KINASE 4/6 (CDK4/6) INHIBITOR LEE011 (=RIBOCICLIB), AND (B) THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR ERLOTINIB, FOR THE TREATMENT OR PREVENTION OF CANCER
Legal status
Patent not validated
Bibliographic data
Indications of the International Patent Classification (IPC)
| (51) |
INT.CL. |
A61K 31/517 |
|
|
|
A61K 31/519 |
|
|
|
A61P 35/00 |
|
European patent
| (11) |
Number of the document |
3340990 |
| (13) |
Kind of document |
T |
| (96) |
European patent application number |
16763585.3 |
|
Date of filing the European patent application |
2016-08-24 |
| (97) |
Date of publication of the European application |
2018-07-04 |
| (45) |
Date of publication and mention of the grant of the patent |
2019-09-25
|
| (46) |
Date of publication of the claims translation |
|
PCT application
| (86) |
Number |
PCT/IB2016/055044 |
|
Date |
2016-08-24 |
PCT application publication
| (87) |
Number |
WO 2017/037576 |
|
Date |
2017-03-09 |
Priority applications
| (30) |
Number |
Date |
Country code |
|
201562211031 P |
2015-08-28
|
US |
Inventors
| (72) |
CAPONIGRO, Giordano, US
HORN-SPIROHN, Thomas, US
LEHAR, Joseph, US
|
Grantee
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
Title
| (54) |
PHARMACEUTICAL COMBINATIONS COMPRISING (A) THE CYCLIN DEPENDENT KINASE 4/6 (CDK4/6) INHIBITOR LEE011 (=RIBOCICLIB), AND (B) THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR ERLOTINIB, FOR THE TREATMENT OR PREVENTION OF CANCER |
| |
PHARMACEUTICAL COMBINATIONS COMPRISING (A) THE CYCLIN DEPENDENT KINASE 4/6 (CDK4/6) INHIBITOR LEE011 (=RIBOCICLIB), AND (B) THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR ERLOTINIB, FOR THE TREATMENT OR PREVENTION OF CANCER |
